Welcome to nudaPETides. Coming soon.

The prescribing platform for veterinary peptide medicine. For licensed veterinarians.

Formulary
Blend. Recovery.Dog. CatTier B

Wolverine

The signature recovery blend. BPC-157 plus TB-500. Full-spectrum tissue repair.

Components

BPC-157 + TB-500

Combined studies

40 referenced

Type

Combination protocol

Full monograph, dosing tables, and prescribing rationale are available to verified veterinarians with an active license and documented VCPR workflow. Request access to unlock the complete formulary library. Request access.

Overview

Wolverine combines the two most studied regenerative peptides into one prescribing protocol. BPC-157 drives gut, tendon, and mucosal repair. TB-500 drives soft tissue, ligament, and cardiovascular repair. Together they cover the widest spectrum of tissue regeneration currently available in compounded veterinary peptide medicine.

Named for the wolverine. Named for a reason. This is the repair blend.

Mechanism of action

  1. 01BPC-157 modulates the nitric oxide system and drives angiogenesis at injury sites.
  2. 02TB-500 binds G-actin and enables cell migration into damaged tissue.
  3. 03Combined action addresses both vascular and cellular components of tissue repair.
  4. 04BPC-157 anchors gastrointestinal and neurologic repair.
  5. 05TB-500 anchors musculoskeletal and cardiovascular repair.

Molecular data

ComponentDetail
BPC-157Pentadecapeptide. 15 amino acids.
TB-500Thymosin beta-4 fragment. 43 amino acids.
RouteSubcutaneous

Species applicability

Dog

Same as the individual monographs. Complex recovery involving multiple tissue types.

Cat

Post-surgical and soft-tissue recovery, following the individual monographs.

Prescribing indications

RecoveryMOST EFFECTIVE

Complex post-surgical recovery involving multiple tissue types.

MusculoskeletalMOST EFFECTIVE

Severe soft tissue and tendon injury.

RecoveryEFFECTIVE

Working and performance dog conditioning under veterinary oversight.

Dosing framework

Full monograph, dosing tables, and prescribing rationale are available to verified veterinarians with an active license and documented VCPR workflow. Request access to unlock the complete formulary library.

Request access

Reconstitution and administration

Full monograph, dosing tables, and prescribing rationale are available to verified veterinarians with an active license and documented VCPR workflow. Request access to unlock the complete formulary library.

Request access

What to expect

Week 1 to 2Reduced pain at injury sites. Improved comfort.
Week 2 to 4Improved gait and function across tissue types.
Week 4 to 8Sustained multi-tissue recovery.

Research library

See individual monographs for BPC-157 and TB-500. Combination protocol rationale rests on the additive mechanisms.BPC-157TB-500 monograph and evidence library.TB-500

Related peptides

BPC-157

Recovery

View

TB-500

Musculoskeletal

View

GLOW

Blend. Dermatologic.

View

The Wolverine blend is dispensed only as a patient-specific compounded prescription under FDA GFI 256. Not an office stock product. Not a mass-produced formulation.

Regulatory footing

This monograph describes a compounded veterinary medication available by prescription only through a licensed veterinarian inside an active veterinarian-client-patient relationship. Not FDA-approved for animal or human use. Compounded on a patient-specific basis under FDA Guidance for Industry #256. For educational use by licensed veterinarians. Not intended for consumer self-prescribing.

For licensed veterinarians only. Compounded under FDA GFI 256. Not FDA-approved.